In the same group of 66 patients with ovarian mCRC, we calculated the ADNEX model without CA-125—no patient had an ADNEX-meta-% value higher than the ADNEX-primary-% (stage I or II–IV; none would be suspected for metastatic origin), while eight patients (12.1%) had higher ADNEX-meta-RR than ADNEX-primary-RR (stage I or II–IV) values (only this fraction of patients would be suspected of having metastatic tumors). The gene discussed is MUC16; the disease is metastatic neoplasm.